EDUCATION EVENTS MUSIC PRINTING PUBLISHING PUBLICATIONS RADIO TELEVISION WELFARE

   
f o r    m a n a g i n g    t o m o r r o w
SEARCH
 
 
APRIL 8, 2007
 Cover Story
 Editorial
 Features
 Trends
 Bookend
 Money
 BT Special
 Back of the Book
 Columns
 Careers
 People

Mobile Security
Today, it is all about information and how the right information is sent to the right people at the right time and right place. Uncertainty about how to secure mobile phones in the face of increasing threats is slowing individual adoption of mobile applications. There are many facets of mobile security, including network intrusion, mobile viruses, spam and mobile phishing. Analysts expect big telecom companies to develop security solutions on various security platforms.


Rough Ride
These are competitive times for the Indian aviation industry. As salaries zoom, players are scrambling to find profits. Even the state-owned Indian is now seeking young airhostesses to take on the competition. It is planning to introduce a voluntary retirement scheme for airhostesses above 40 years. On an average, they draw a salary of Rs 5 lakh a year. The salaries of pilots, too, are soaring. According to industry estimates, the country needs over 3,000 pilots over the next five years.
More Net Specials

Business Today,  March 25, 2007

 
 
Young Globaliser
 
NAME: MALVINDER MOHAN SINGH
AGE: 34
DESIGNATION: Managing Director
COMPANY: Ranbaxy Laboratories
Malvinder Singh's global ambitions (he made eight global acquisitions last year) now make him the only Indian suitor left in the fray for Merck's generics business. But he's not desperate for his prize. Singh, who made a non-binding bid for the $6-billion (Rs 26,400-crore) division (it's double of Ranbaxy's market value), has said: "We are not in a rat race for acquisitions. We are focussed on creating value for our shareholders in the best way we can." But this is not the only global fight he has on his hands. With nine "first-to-file" products under litigation in the us, the company's age-old spat with Pfizer has reached a higher level; the latter has filed patent-related litigation against Ranbaxy to stall the launch of its low-cost generic form of best-selling blood pressure medicine Caduet. An unfazed Singh has decided to fight back and challenge Pfizer's petition. He believes that "when non-infringing products are developed, such efforts must be rewarded". Needless to say, the litigations have delayed his plans of launching generic versions of several blockbuster drugs in the US over the next five-six years.

The 34-year-old CEO, who was "surprised" by the us Food and Drug Administration's raids on his company's New Jersey facilities in February this year, meanwhile, is involved in another litigation in the us; this time, a consumer group, the Boston-based Prescription Action Litigation, is suing Ranbaxy for allegedly delaying the us launch of Modafinil, the generic version of Cephalon's sleep disorder drug Provigil. The western media, typically, has branded him a copycat. The Guardian called his flagship the Indian specialist in "copycat drugs", but Singh, who enjoys huge goodwill in his home market and elsewhere, can afford to brush this off. His series of acquisitions in the European market last year seem to be paying off. The company's subsidiary in Romania, Terapia Ranbaxy (which he acquired last year), has a market share of 5.6 per cent and has recently received Market Authorisations (MAS) for 20 new products. His rivals may not like it, but he's winning-fair and square; and for Singh, and his country of origin, that's what matters.

 

    HOME | EDITORIAL | COVER STORY | FEATURES | TRENDS | BOOKEND | MONEY
BT SPECIAL | BOOKS | COLUMN | JOBS TODAY | PEOPLE

 
 
   

INDIA TODAY | INDIA TODAY PLUS | BT EVENTS
ARCHIVESCARE TODAY | MUSIC TODAY | ART TODAY | SYNDICATIONS TODAY